BioVie Investor Relations Material
Latest events
AGM 2025
BioVie
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioVie Inc
Access all reports
BioVie Inc. is a clinical stage biopharmaceutical company based in the United States, focusing on the discovery, development, and commercialization of innovative drugs for the treatment of chronic debilitating conditions. The company's pipeline includes key drug candidates like BIV201 for the treatment of ascites due to chronic liver cirrhosis as well as NE3107, aimed at treating neurodegenerative disorders. NE3107 is in clinical trial for mild to moderate Alzheimer's disease and Parkinson's disease. It is headquartered in Carson City, Nevada, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
BIVI
Country
🇺🇸 United States